| Shen, Feng |
| Not yet recruiting | 4 | 336 | RoW | Danning Tablet, Biliflow (NPN 80073325, manufactured by Shanghai Hutchison Pharmaceuticals Limited) | Eastern Hepatobiliary Surgery Hospital | Polyps Gallbladder | 08/24 | 11/24 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
| Not yet recruiting | 3 | 165 | RoW | TQB3454 tablets, TQB3454 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Biliary Carcinoma | 12/26 | 12/26 | | |
NCT05913336: A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU |
|
|
| Recruiting | 1/2 | 20 | RoW | Remimazolam Tosilate | Jiangsu HengRui Medicine Co., Ltd. | Sedation in the ICU | 11/23 | 11/23 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
NCT05292443: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer |
|
|
| Withdrawn | N/A | 300 | RoW | Observation | Geneplus-Beijing Co. Ltd., Eastern Hepatobiliary Surgery Hospital | Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma | 03/23 | 03/23 | | |
| Zhang, Qian |
NCT06090994: Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy |
|
|
| Not yet recruiting | 4 | 756 | RoW | Huaier granule, Z20000109（NMPA Approval Number）, Capecitabine | Fudan University, Huazhong University of Science and Technology | Colorectal Cancer | 07/27 | 11/29 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
| Recruiting | 1 | 30 | RoW | GC203 TIL(gene-edited TIL) or autologous TILs | Shanghai Juncell Therapeutics, Third Affiliated Hospital of Naval Medical University | Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy | 06/26 | 06/27 | | |
NCT05098392: Sibling-Mediated Intervention on Literacy and Reciprocity for Children With Autism |
|
|
| Recruiting | N/A | 40 | US, RoW | Sibling-mediated intervention | Arizona State University | Autism Spectrum Disorder | 02/25 | 11/25 | | |
NCT06730334: Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS) |
|
|
| Recruiting | N/A | 400 | RoW | | Nanjing Medical University | Psoriatic Arthritis, Secukinumab, Ultrasonography | 09/26 | 06/28 | | |
NCT06764290: Neural Changes in Stroke Patients During Challenging Walking Tasks. |
|
|
| Recruiting | N/A | 60 | RoW | pedal walking, visual occlusion | Nanjing Medical University | Stroke | 01/25 | 02/25 | | |
NCT04433455: Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients |
|
|
| Recruiting | N/A | 20 | RoW | | Huashan Hospital | Hemodialysis, Cognitive Impairment, Cerebrovascular Disorders | 05/25 | 05/25 | | |
| Wang, Kui |
| Active, not recruiting | 2 | 43 | RoW | Pembrolizumab+Lenvatinib | Shanghai Zhongshan Hospital, Merck Sharp & Dohme LLC | Carcinoma, Hepatocellular | 12/23 | 07/25 | | |
NCT04000737: YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 125 | US, RoW | YIV-906+Sorafenib, Placebo+Sorafenib | Yiviva Inc. | Advanced Hepatocellular Carcinoma | 12/23 | 05/24 | | |
| Not yet recruiting | 2 | 30 | RoW | Cadonilimab+Lenvatinib | Shanghai Zhongshan Hospital, Sun Yat-sen University, Eastern Hepatobiliary Surgery Hospital | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
TQB2618-AK105-Ib-04, NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
| Yu, Wenlong |
| Recruiting | 1 | 30 | RoW | GC203 TIL(gene-edited TIL) or autologous TILs | Shanghai Juncell Therapeutics, Third Affiliated Hospital of Naval Medical University | Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy | 06/26 | 06/27 | | |
| Tai, Xiaoyun |
| Recruiting | 1 | 30 | RoW | GC203 TIL(gene-edited TIL) or autologous TILs | Shanghai Juncell Therapeutics, Third Affiliated Hospital of Naval Medical University | Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy | 06/26 | 06/27 | | |
